StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by AngelMan92on Aug 14, 2020 11:54pm

103 Views

Post# 31411781

RE:RE:99K in Revenue LOL

You can't pull numbers out of nowhere dude, they did their research in comparing how much is spent on testing for these cancers each year. CANCER IS A TRILLION DOLLAR INDUSTRY.

skiboard09 wrote:

Why put Aristotle is a 35 billion opportunity. Seems again throwing around massive numbers to come nowhere close to it.

If this test really caught on. With our current testing ability they won't be generating much revenue.